UPM Institutional Repository

Frequently reported blood biomarkers in sarcopenia clinical trials: a systematic review and meta-analysis


Citation

Calluy, Emma and Malrechauffé, Yveline and Boretti, Emma and Van Heden, Sophie and Sanchez-Rodriguez, Dolores and Chan, Yoke Mun and Cavalier, Etienne and Ladang, Aurélie and Reginster, Jean Yves and Douxfils, Jonathan and Beaudart, Charlotte (2026) Frequently reported blood biomarkers in sarcopenia clinical trials: a systematic review and meta-analysis. Aging Cell, 25 (2). art. no. e70361. pp. 1-27. ISSN 1474-9718; eISSN: 1474-9726

Abstract

This systematic review and meta-analysis aims to identify the most frequently reported blood-based biomarkers (BBMs) in randomised controlled trials (RCTs) addressing sarcopenia management, and to perform a preliminary evaluation of the effects of sarcopenia-specific interventions on BBMs concentrations. Medline, Embase and CENTRAL databases were searched to retrieve RCTs published until March 2024 (PROSPERO: CRD42024603238) on older participants with sarcopenia. Eligible studies applied a consensus definition of sarcopenia and reported BBM values before and after intervention. Meta-analyses were performed for BBMs reported in a minimum of 2 RCTs using a random effects model with a standardised mean difference (SMD) and a 95% confidence interval. Among 58 RCTs on sarcopenia management, only 21 (36.2%) assessed BBMs and none involved pharmacological interventions. Altogether, 47 distinct BBMs were identified. The most frequently reported were C-reactive protein, interleukin 6, tumour necrosis factor α, Insulin-like Growth Factor 1 (IGF-1). Muscle-specific BBM, follistatin, growth differentiation factor 8 and 15 were assessed in only 2 RCTs. Among non-muscle-specific BBMs, IGF-1 was significantly impacted by the studied interventions (SMD = 0.46, CI = [0.04; 0.88]). However, this change was not significant when analyses were restricted to RCTs reporting significant improvement in key sarcopenia measures. Despite substantial heterogeneity, few BBMs assessed in sarcopenia RCTs were muscle-specific and limited biomarkers responded to interventions. There is an urgent need to adopt recommendations regarding muscle-specific BBMs to be assessed in sarcopenia RCTs. Developing a standardised Core Outcome Set for sarcopenia intervention studies would enhance the standardisation of sarcopenia RCTs and ultimately improve disease management.


Download File

[img] Text
123451.pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB)

Additional Metadata

Item Type: Article
Subject: Aging
Subject: Cell Biology
Divisions: Faculty of Medicine and Health Science
Malaysian Research Institute on Ageing
DOI Number: https://doi.org/10.1111/acel.70361
Publisher: John Wiley and Sons
Keywords: Biomarkers; Meta-analysis; Randomised controlled trials; Reference standards; Sarcopenia
Depositing User: MS. HADIZAH NORDIN
Date Deposited: 10 Mar 2026 02:42
Last Modified: 10 Mar 2026 02:42
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1111/acel.70361
URI: http://psasir.upm.edu.my/id/eprint/123451
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item